Autoimmune lymphoproliferative syndrome other imaging findings: Difference between revisions
No edit summary |
|||
| Line 2: | Line 2: | ||
{{Autoimmune lymphoproliferative syndrome}} | {{Autoimmune lymphoproliferative syndrome}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
| Line 12: | Line 9: | ||
[[PET]] [[scan]] can be an useful tool to minimize the number of [[lymph nodes]] to get biopsied based on degree of FDG acitivity in [[ALPS]] pateints with [[lymphoma]].FDG distribution in [[ALPS]] might be helpful to distiguish between [[ALPS]] [[adenopathy]] and [[ALPS]] associated [[lymphoma]]. <ref name="RaoOliveira2011">{{cite journal|last1=Rao|first1=V. Koneti|last2=Oliveira|first2=João Bosco|title=How I treat autoimmune lymphoproliferative syndrome|journal=Blood|volume=118|issue=22|year=2011|pages=5741–5751|issn=0006-4971|doi=10.1182/blood-2011-07-325217}}</ref> | [[PET]] [[scan]] can be an useful tool to minimize the number of [[lymph nodes]] to get biopsied based on degree of FDG acitivity in [[ALPS]] pateints with [[lymphoma]].FDG distribution in [[ALPS]] might be helpful to distiguish between [[ALPS]] [[adenopathy]] and [[ALPS]] associated [[lymphoma]]. <ref name="RaoOliveira2011">{{cite journal|last1=Rao|first1=V. Koneti|last2=Oliveira|first2=João Bosco|title=How I treat autoimmune lymphoproliferative syndrome|journal=Blood|volume=118|issue=22|year=2011|pages=5741–5751|issn=0006-4971|doi=10.1182/blood-2011-07-325217}}</ref> | ||
[[File:PET ALPS.jpeg|center|thumb|520x520px|CT and FDG-PET scans featuring ALPS-FAS–associated lymphadenopathy and splenomegaly.<ref name="RaoOliveira2011" />]] | [[File:PET ALPS.jpeg|center|thumb|520x520px|CT and FDG-PET scans featuring ALPS-FAS–associated lymphadenopathy and splenomegaly.<ref name="RaoOliveira2011" />]] | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Revision as of 02:42, 6 July 2021
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome other imaging findings On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome other imaging findings |
|
FDA on Autoimmune lymphoproliferative syndrome other imaging findings |
|
CDC on Autoimmune lymphoproliferative syndrome other imaging findings |
|
Autoimmune lymphoproliferative syndrome other imaging findings in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome other imaging findings |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Fluorodeoxyglucose positron emission tomography (FDG-PET) may be helpful in the diagnosis of Autoimmune lymphoproliferative syndrome(ALPS) by distinguishing benign lymphadenopathy from malignant lymphadenopathy.
Other Imaging Findings
PET scan can be an useful tool to minimize the number of lymph nodes to get biopsied based on degree of FDG acitivity in ALPS pateints with lymphoma.FDG distribution in ALPS might be helpful to distiguish between ALPS adenopathy and ALPS associated lymphoma. [1]
